Fierce Pharma

For Sanofi, Dupixent's surge overcomes shortfall in vaccine sales

Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the ...
CNN

Regeneron Collaborations on Dupixent® (dupilumab) Highlighted During Sanofi R&D Investor Event

Dupixent meets early efficacy threshold for continuation in ongoing Phase 3 trial of patients with COPD; second confirmatory trial will commence in third quarter of 2020 Regeneron Pharmaceuticals, Inc ...

Regeneron beats quarterly estimates on strong demand for Dupixent

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

Regeneron tops quarterly estimates, plans to resubmit Eylea application

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...
Reuters

Sanofi and Regeneron's Dupixent wins EU approval to treat children

PARIS, Nov 30 (Reuters) - Healthcare companies Sanofi (SASY.PA), opens new tab and Regeneron (REGN.O), opens new tab said on Monday that their Dupixent product has won approval from the European ...
Benzinga.com

Regeneron Pipeline Aims To Address $220 Billion Therapeutic Opportunities By 2030

Dupixent (dupilumab) is now used to treat over a million patients globally. The recent approval and launch in chronic obstructive pulmonary disease (COPD) have had a successful start, with coverage ...